Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
Contineum Therapeutics director Diego Miralles received a new stock option grant as part of standard board compensation. He was awarded options over 19,000 shares of Class A common stock at an exercise price of $14.19 per share under the company’s 2024 Equity Incentive Plan.
The grant was made pursuant to Contineum’s Non-Employee Director Compensation Program, which provides an automatic option for 19,000 shares after each regular annual meeting for continuing non-employee directors. The options vest in full on the earlier of June 26, 2027, or the next regular annual stockholder meeting, subject to his continuous service, and expire on June 25, 2036. Following this grant, Miralles holds 19,000 stock options directly.
Contineum Therapeutics, Inc. director Lori Lyons-Williams received a grant of stock options covering 19,000 shares of Class A Common Stock under the company’s 2024 Equity Incentive Plan. The options have an exercise price of $14.19 per share and expire on June 25, 2036.
The grant was made pursuant to Contineum’s Non-Employee Director Compensation Program, which provides an automatic annual option award to each continuing non-employee director after the regular annual stockholder meeting. The option vests in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting, subject to her continuous service.
Contineum Therapeutics director Olivia C. Ware received a grant of stock options for 19,000 shares of Class A common stock. The options have an exercise price of $14.19 per share and were issued under the 2024 Equity Incentive Plan as part of the non-employee director compensation program. They vest in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting, assuming continuous board service.
Contineum Therapeutics director Evert B. Schimmelpennink received a routine equity grant. He was granted stock options for 19,000 shares of Class A Common Stock at an exercise price of $14.19 per share under the 2024 Equity Incentive Plan. These options vest in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting and expire on June 25, 2036. This is a compensation-related award, not an open-market purchase or sale.
Contineum Therapeutics director Troy A. Ignelzi received a grant of stock options for 19,000 shares of Class A Common Stock. The options were awarded under the company’s 2024 Equity Incentive Plan and Non-Employee Director Compensation Program at an exercise price of $14.19 per share.
The option grant vests in full on the earlier of June 26, 2027 or the next regular annual meeting of stockholders, assuming continuous board service. Following this award, Ignelzi holds stock options for 19,000 underlying shares directly.
Contineum Therapeutics director Todd R. Brady received a grant of stock options for 19,000 shares of Class A Common Stock. The options have a $14.19 exercise price, were granted under the 2024 Equity Incentive Plan, and vest in full on June 26, 2027 or at the next annual stockholder meeting.
Contineum Therapeutics, Inc. director Sarah Boyce received a grant of stock options covering 19,000 shares of Class A common stock. The options have an exercise price of $14.19 per share and were issued under the company’s 2024 Equity Incentive Plan as part of its Non-Employee Director Compensation Program.
According to the terms, the options will vest in full on the earlier of June 26, 2027, or the next regular annual meeting of stockholders, provided she continues to serve as a director. This is a routine compensation-related award and does not involve any open-market buying or selling of shares.
Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. As of the record date of April 27, 2026, there were 32,723,877 shares of Class A common stock outstanding and entitled to vote.
Stockholders elected three Class II directors to serve until the 2029 annual meeting. Evert Schimmelpennink received 21,773,559 votes for and 131,384 withheld; Lori M. Lyons-Williams received 20,593,715 for and 1,311,228 withheld; and Diego Miralles, M.D. received 21,673,187 for and 231,756 withheld. Each proposal had 6,133,812 broker non-votes.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,021,047 votes for, 16,104 against and 1,604 withheld.
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of 4,170 shares of Class A Common Stock at a weighted average price of $13.1564 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
After this transaction, he holds 139,372 shares directly and 10,110 shares indirectly through his spouse. His holdings include 3,268 shares purchased through Contineum’s Employee Stock Purchase Plan on May 15, 2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of Common stock tied to Restricted Stock Units. The filing lists 4170 (unit) entries and documents multiple 10b5-1 sales by Daniel Lorrain on 05/01/2026, 04/06/2026 and 03/02/2026 with dollar amounts shown alongside each entry.